PDIA4 and glioblastoma: By combining follow-up data and quantified IHC scores, patients with GBM were classified from high expression of PDIA4 to low, and Kaplan–Meier analysis also confirmed that clinical GBM patients with higher protein expression of PDIA4 had a shorter survival period and lower survival rate (Fig. 1I).